The company outlined its plans to launch a kidney transplant rejection test that is based on cell-free DNA in 2019 and described its progress in breast cancer research.
Though there are few direct hints at how the company plans to translate its findings to a clinical test, its early data has captured the attention of the cancer community.
Evidence is accumulating that analyzing cell-free DNA and/or samples from circulating tumor cells provides a good surrogate for bone marrow in these patients.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.
